• About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services
  • About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services

Philogen to attend World ADC on March 3-6, 2025

by Lisa Nadal | Mar 22, 2025 | Past Events, Scientific

Andrea Galbiati is giving a presentation about Philochem’s FAP-targeted small molecule therapeutics on March 5 (main session), entitled “Detailing Clinical Development of OncoFAP: a Small Molecule Conjugate Targeting Fibroblast Activation Protein in Solid...

Philogen to attend the European Association of Nuclear Medicine (EANM) annual meeting on October 19-23, 2024

by Lisa Nadal | Oct 15, 2024 | Past Events

Andrea Galbiati is giving a presentation about Philochem’s FAP-targeted radioligand therapeutics on October 20 (session 604), entitled “Development of Multivalent OncoFAP Derivatives for the Tumor-Targeted Delivery of Theranostic Radionuclides”. Dr. Sebastian Oehler...

2024 EFMC Prize for Young Medicinal Chemist or Chemical Biologist in Industry for Samuele Cazzamalli, Head of Chemistry at Philochem

by last | Sep 4, 2024 | 2024, Past Events, Press Releases

Dr. Samuele Cazzamalli, Head of Chemistry at Philochem, will be awarded the 2024 EFMC Prize for Young Medicinal Chemist or Chemical Biologist in Industry. 2024_EFMC_Prize_for Young_Medicinal_Chemist

Philochem to attend the Festival of Biologics 2024 in Basel (15-17 October 2024)

by Lisa Nadal | Aug 21, 2024 | Past Events

Dr. Andrea Galbiati will give a talk entitled “Small Molecule Therapeutics targeting Fibroblast Activation Protein in the tumor microenvironment” Dr. Ettore Gilardoni will give a talk entitled: “Mass Spectrometry applications for Host Cell Protein Analysis...

Philochem to attend the 23rd Human Proteome Organization World Congress as presenting authors on October 20-24, 2024 in Dresden, Germany)

by Lisa Nadal | Jul 16, 2024 | 2024, Past Events, Scientific

Philochem will participate at the 23rd HUPO Congress in October, presenting two posters: Domenico Ravazza (3rd year Ph.D. student): Mass spectrometry as a quantitative methodology to assess the biodistribution of monoclonal antibodies Lucrezia Principi (2nd year Ph.D....

Philochem to attend the 72nd ASMS Conference on Mass Spectrometry and Allied Topics in Anaheim on June 2-6, 2024

by Lisa Nadal | May 24, 2024 | Past Events

Dr. Ettore Gilardoni (Head of Mass Spectrometry) will attend the 72nd ASMS conference in Anaheim (2-6 June 2024) and present a poster entitled: “Mass Spectrometry evaluation of glycosylation variants and SP2/0 Host Cell Proteins during downstream processes: the case...
« Older Entries

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025
  • Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties
  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
Privacy Policy / Cookie Policy

Contacts

  • Follow

Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch